TW-37

製品コードS1121

TW-37化学構造

分子量(MW):573.7

TW-37は一種の新たな非ペプチド類阻害剤で、無細胞試験で、組替えのBcl-2、Bcl-xLとMcl-1に作用する時のKi値が0.29μM、1.11μMと0.26μMにそれぞれ分かれることです。

サイズ 価格(税別) 在庫  
JPY 24236.00 あり
JPY 26560.00 あり
JPY 112880.00 あり

カスタマーフィードバック(8)

  • (a) H23 cells exposed for 0–24 h to TW-37 (10 uM) with and without ZVAD.fmk (50 uM) were monitored for apoptotic morphology using electron microscopy (scale bar, 5 mm). % PS positive cells indicate the percentage of apoptotic cells, characterised by PS externalisation.

    Cell Death Differ 2013 20, 1475-84. TW-37 purchased from Selleck.

    (b) Whole-cell lysates of H23 cells exposed for 0–24 h to TW-37 (10 uM) were probed with antibodies against PARP and caspase-9. The appearance of both the p89 processed form of PARP and the p35 form of caspase-9 were characteristic of the intrinsic pathway of apoptosis.

    Cell Death Differ 2013 20, 1475-84. TW-37 purchased from Selleck.

  • (c) Whole-cell lysates of BAK-reconstituted and -deficient Jurkat cells exposed for 0–24 h to TW-37 (10 uM ) were probed as in B. % PS positive cells indicate the percentage of apoptotic cells, characterised by PS externalisation.

    Cell Death Differ 2013 20, 1475-84. TW-37 purchased from Selleck.

    (d) Electron micrographs of control and TW-37 (10 uM for 24 h); treated BAK-reconstituted and -deficient Jurkat cells reveal a dependence on BAK for TW-37- mediated apoptosis (scale bar, 5 um)

    Cell Death Differ 2013 20, 1475-84. TW-37 purchased from Selleck.

  • MCL-1 is a key anti-apoptotic BCL-2 family member that regulates ER membrane reorganisation. (a) Pan-BCL-2 family inhibitors induce ER membrane reorganisation more potently than BCL-2 and BCL-XL-specific inhibitors. Apogossypol (10 μM) and TW37 (20 μM) induced extensive membrane reorganisation, assessed by BAP31 staining in HeLa cells, within 4 h of exposure, whereas ABT-737 (20 μM) induced modest reorganisation after 8 h and the inactive enantiomer ABT-737E (20 μM) failed to induce reorganisation (scale bar, 20 μm).

    Cell Death Differ 2012 19, 1896-907. TW-37 purchased from Selleck.

    Cytotoxicity of TW-37 monotherapy. TTC549 cells and KP-MRTRY cells were seeded in 96-well plates, incubated for 24 h, treated with TW-37 (0-1,000 nM), and then analyzed. TW-37 IC50 values for the TTC549 and KP-MRT-RY cell lines were 554 and 588 nM, respectively.

    J Cell Physiol, 2016, 231(9):1932-40. TW-37 purchased from Selleck.

  • MEF cells were treated for  24 hours with the Bcl-2 antagonists  TW-37at the indicated doses.Acute survival was monitored by propidium iodide uptake assays(red lines).Long term survival(red line) was measured by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

    Dr. Christine Hawkins of La Trobe University. TW-37 purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100 nm TW-37.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. TW-37 purchased from Selleck.

製品安全説明書

Bcl-2阻害剤の選択性比較

生物活性

製品説明 TW-37は一種の新たな非ペプチド類阻害剤で、無細胞試験で、組替えのBcl-2、Bcl-xLとMcl-1に作用する時のKi値が0.29μM、1.11μMと0.26μMにそれぞれ分かれることです。
ターゲット
Mcl-1 [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
0.26 μM(Ki) 0.29 μM(Ki) 1.11 μM(Ki)
体外試験

TW-37 targets the BH3-binding groove in Bcl-2 where proapoptotic Bcl-2 proteins bind, and shows higher affinity and selectivity for Bcl-2 and Mcl-1 over Bcl-xL with Ki values of 0.29 μM, 0.26 μM and 1.11 μM, respectively. [1] In vitro, TW-37 shows significant anti-proliferative and pro-apoptotic effect in a de novo chemo-resistant WSU-DLCL2 lymphoma cell line and primary cells obtained from a lymphoma patient without effects on normal peripheral blood lymphocytes. [1] TW-37 exhibits the inhibitory effect on both cell growth and cell death in endothelial cell with IC50 of approximately 1.8 μM without effect on the fibroblasts exposed to the same concentration range as the endothelial cells. In addition, TW37 also shows the anti-proliferation effects in MCF-7, LNCaP, and SLK tumor cell lines with the same or lower concentration range than those required to inhibit endothelial cell growth. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human JAR cell M4HW[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1zFXGlvcGmkaYTpc44hd2ZiaIXtZY4hUkGUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj62JI5O NHnKSZdUSU6JRWK=
human Ca9-22 cell NITieGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvuVIJQUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njh{IH7N NWfzUoJRW0GQR1XS
human CHL-1 cell M4C5N2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlHKTY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlkhdk1? NYLhO2t7W0GQR1XS
human A549 cell NFPhdXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHXjO5pKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE4xQSCwTR?= MVvTRW5ITVJ?
human RKO cell NUPWUXhET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXvoXXV[UW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4yPyCwTR?= NX7JRYtUW0GQR1XS
human GCIY cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYPzcZRTUW6qaXLpeIlwdiCxZjDoeY1idiCJQ1nZJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlAvQDNibl2= NEXucnpUSU6JRWK=
human BHT-101 cell M2nUTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVm3R2w2UW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjFwOEOgcm0> NYPhNYVFW0GQR1XS
human Hs-578-T cell NH7BO|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGh{NTV5OD3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlMvPTlibl2= M3PqZXNCVkeHUh?=
human SK-UT-1 cell NIXLOnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUHJcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE43QCCwTR?= M{PwcHNCVkeHUh?=
human NB7 cell NFP6cY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXfJcohq[mm2aX;uJI9nKGi3bXHuJG5DPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJ7LkK4JI5O M320XXNCVkeHUh?=
human YKG-1 cell NIjNV5RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2ix[GlvcGmkaYTpc44hd2ZiaIXtZY4hYUuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPU44PiCwTR?= NYTBT45RW0GQR1XS
human HuH-7 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mo\tTY5pcWKrdHnvckBw\iCqdX3hckBJfUhvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOyMlgzKG6P Mlu4V2FPT0WU
human SAS cell NIrzS3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkfQTY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Mz6xPEBvVQ>? NUi0bnpuW0GQR1XS
human UACC-62 cell MlLMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4PNTWlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQz22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjN3IH7N MnL6V2FPT0WU
human AGS cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGXMUWRKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO3MlU{KG6P MV7TRW5ITVJ?
human SK-MEL-30 cell MoDHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml3xTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Py57NzDuUS=> M4DxOHNCVkeHUh?=
human A427 cell NHf1NIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoPGTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NESuOlkhdk1? M1W5NnNCVkeHUh?=
human DU-145 cell NHK4cHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1zuTmlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvMUS1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVIvOTNibl2= MXPTRW5ITVJ?
human HCT-116 cell NUXkWYVrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYC5ZoVSUW6qaXLpeIlwdiCxZjDoeY1idiCKQ2StNVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTJwNk[gcm0> MXvTRW5ITVJ?
human A673 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIexVpRKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21N{45PSCwTR?= MkDwV2FPT0WU
human SF126 cell Ml[4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWLJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUeuNFchdk1? MUjTRW5ITVJ?
human SW872 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnjhTY5pcWKrdHnvckBw\iCqdX3hckBUXzh5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUW4Mlkhdk1? M{D5dnNCVkeHUh?=
human NCI-H1581 cell Ml7XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MULJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW4NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVY4NjZ2IH7N NXW2PIZuW0GQR1XS
human SK-MEL-5 cell M17YWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OlkvOjVibl2= M4nuPXNCVkeHUh?=
human CP50-MEL-B cell M3\BSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mk\DTY5pcWKrdHnvckBw\iCqdX3hckBEWDVyLV3FUE1DKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjlwNUmgcm0> MYjTRW5ITVJ?
human YH-13 cell MojDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmTyTY5pcWKrdHnvckBw\iCqdX3hckB[UC1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUewMlU6KG6P NEi4PIpUSU6JRWK=
human LXF-289 cell MmjMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmLvTY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|IvQDVibl2= M4K5N3NCVkeHUh?=
human MC-IXC cell M1LQSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEPFVpFKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVc2NjN|IH7N M2DvUXNCVkeHUh?=
human NB14 cell NGDufoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVP2R4dkUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|YvPDVibl2= NEXzO4VUSU6JRWK=
human HEC-1 cell Ml;YS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnLuTY5pcWKrdHnvckBw\iCqdX3hckBJTUNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUixMlM4KG6P MnnBV2FPT0WU
human U-87-MG cell M{PEXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHUuQDdvTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24Nk4zPCCwTR?= MnnBV2FPT0WU
human HOS cell NFXsWodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn64TY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16ND63NUBvVQ>? NIX5T5NUSU6JRWK=
human HUTU-80 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUPJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24O{4xOSCwTR?= MWDTRW5ITVJ?
human A375 cell NEDaOIFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVrJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16OD64N{BvVQ>? NXOxdXRYW0GQR1XS
human A204 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml7PTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OUeuPFQhdk1? M3vvW3NCVkeHUh?=
human GB-1 cell NYe2[Ih2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MonrTY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OUiuOlkhdk1? M1TPNnNCVkeHUh?=
human MDA-MB-231 cell NVnJO282T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XBXGlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUC4NFch|ryP MVrTRW5ITVJ?
human SW982 cell MoS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXG3RmNLUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTFyNzFOwG0> MXrTRW5ITVJ?
human SW756 cell NUXhXYVPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NU\zWotUUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF{M{[g{txO NFexZYhUSU6JRWK=
human MG-63 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmjCTY5pcWKrdHnvckBw\iCqdX3hckBOTy14MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEzPDhizszN MXrTRW5ITVJ?
human Daoy cell MmfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn\ITY5pcWKrdHnvckBw\iCqdX3hckBF[W:7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOFA4OyEQvF2= NEfMToFUSU6JRWK=
human MDA-MB-453 cell NFXYXVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlHKTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtOFU{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUG4PEDPxE1? MnnRV2FPT0WU
human HT-144 cell NVXzfHJwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mlz0TY5pcWKrdHnvckBw\iCqdX3hckBJXC1zNESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE2OjBzIN88US=> NEG5XXFUSU6JRWK=
human LoVo cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFXHZoxKdmirYnn0bY9vKG:oIHj1cYFvKEyxVn:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE3ODl|IN88US=> M3f1SHNCVkeHUh?=
human NY cell NUX4[VlDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUXTe4J7UW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVc4PjJizszN NHvsNIpUSU6JRWK=
human SW1783 cell M3[wTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEXHSm5KdmirYnn0bY9vKG:oIHj1cYFvKFOZMUe4N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjF|MEGg{txO NWn6ZWNHW0GQR1XS
human A2780 cell NUDVSWRKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVfJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNVg1PiEQvF2= MnPFV2FPT0WU
human MDA-MB-361 cell NGX6e3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVTJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ{NkSg{txO NGfwT5ZUSU6JRWK=
human RPMI-2650 cell Mn3KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;PTmNKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtNlY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkO4N|Eh|ryP MX3TRW5ITVJ?

多くの細胞株試験データを見る場合、クリックしてください

体内試験 TW-37 shows a maximum tolerated dose (MTD) of 40 mg/kg for three i.v. injections in severe combined immunodeficient (SCID) mice when given alone, and enhances tumor inhibitory effect of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) regimen. [1] TW-37, administrated by i.v. produces the antiangiogenic effect by decreasing the density of functional human microvessels in the severe combined immunodeficient mouse model of human angiogenesis. [2] The combination of TW-37 and MEK inhibitors synergistically block melanoma cell growth in mice by a significant reduction in tumor volume and tumor mass. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Fluorescence polarization-based binding assay for recombinant Bcl-2, Bcl-XL, and Mcl-1 protein :

For this assay, the 21-residue BH3 peptide QEDIIRNIARHLAQVGDSMDR derived from Bid labeled with 6-carboxyfluorescein succinimidyl ester (FAM-Bid) and recombinant proteins derived from human Bcl-2,Bcl-X L,and Mcl-1 are employed. It is determined that FAM-Bid has a Ki of 11 nM to Bcl-2 protein,25 nM to Bcl-XL protein,and 5.7 nM to Mcl-1 protein. The competitive binding assay for Bcl-XL is same as that for Bcl-2 with the following exceptions: 30 nM Bcl-XL protein and 2.5 nM FAM-Bid peptide in the following assay buffer [50 mM Tris-Bis (pH 7.4) and 0.01% bovine gamma-globulin].
細胞試験: [2]
+ 展開
  • 細胞株: HDMECs
  • 濃度: 0 - 100 μM
  • 反応時間: 96 hours
  • 実験の流れ: The sulforhodamine B (SRB) cytotoxicity assay is used as described. Briefly, optimal cell density for cytotoxicity assay is determined by growth curve analysis. HDMECs are seeded in a 96-well plate and allowed to adhere overnight. Drug or control is diluted in EGM2-MV and layered onto cells, which are allowed to incubate for times as indicated in the figures. Alternatively, HDMECs are coincubated with TW37 and 0 to 100 ng/mL recombinant human VEGF (rhVEGF)165 or 0 to 100 ng/mL recombinant human CXCL8. Cells are fixed on the plates by addition of cold trichloroacetic acid (10% final concentration) and incubation for 1 hour at 4 °C. Cellular protein is stained by addition of 0.4% SRB in 1% acetic acid and incubation at room temperature for 30 minutes. Unbound SRB is removed by washing with 1% acetic acid and the plates are air dried. Bound SRB is resolubilized in 10 mM unbuffered Tris-base and absorbance is determined on a microplate reader at 560 nm. Test results are normalized against initial plating density and drug-free controls. Data are obtained from triplicate wells per condition and are representative of at least three independent experiments
    (参考用のみ)
動物試験:[3]
+ 展開
  • 動物モデル: Athymic NCr-nu/nu mice bearing SK-Mel-147 melanoma xenografts
  • 製剤: TW-37 is resuspended in 1:1 Tween 80/ethanol (diluted 10-fold in 0.9% saline before use).
  • 投薬量: ~40 mg/kg
  • 投与方法: Administered via i.v. or i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 115 mg/mL (200.45 mM)
Ethanol 4 mg/mL (6.97 mM)
Water Insoluble
体内 順序で溶剤を入れること:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 573.7
化学式

C33H35NO6S

CAS No. 877877-35-5
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Bcl-2信号経路図

Bcl-2 Inhibitors with Unique Features

相関Bcl-2製品

Tags: TW-37を買う | TW-37 ic50 | TW-37供給者 | TW-37を購入する | TW-37費用 | TW-37生産者 | オーダーTW-37 | TW-37化学構造 | TW-37分子量 | TW-37代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID